L

Lipocine
D

LPCN

3.20000
USD
-0.01
(-0.31%)
مغلق
حجم التداول
0
الربح لكل سهم
-2
العائد الربحي
-
P/E
-3
حجم السوق
17,121,139
أصول ذات صلة
A
AMRN
0.025
(0.15%)
16.665 USD
C
CRBP
-0.15750
(-2.03%)
7.60000 USD
M
MNOV
0.04000
(3.15%)
1.31000 USD
المزيد
الأخبار المقالات

العنوان: Lipocine

القطاع: Healthcare
الصناعة: Biotechnology
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.